Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 435-740-7 | CAS number: 94317-64-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
NBPT appears to be biotransformed to N-(n-butyl)thiophosphoric diamide and the glucuronic acid conjugate of NBPT which then hydrolyzes to N-(n-butyl)thiophosphoric diamide. Both metabolites appear to be readily excreted in the urine.
Therefore NBPT and/or its metabolites are not expected to bioaccumulate.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Introduction
The study was conducted according to the requirements of the the guideline EPA OPPTS 870.7485 (Metabolism and Pharmacokinetics) of the United States of America. The study was designed to estimate the extent and rate of elimination of radiolabel in expired air, urine, feces and cage rinses from male Sprague-Dawley rats that received a singlp oral dose of [14C]-N-(n-butyl) thiophosphoric triamide. The liver, mesenteric fat, kidneys, spleen, whole blood and residual carcass also were analyzed for radiolabel content. The study also was designed to generate the blood pharmacokinetic data. In addition, metabolites of NBPT in the urine were characterized and identified.
Method
In the pilot experiment, a single oral dose of [14C]-N-(n-butyl) thiophosphoric triamide (14C]NBPT) was administered at an average of 269 mg/kg body weight (263 µCi/kg body weight) to two male Sprague-Dawley rats. Expired air from each animal was passed through two CO2traps and one volatile organics trap. An average of 40.22 percent of the administered dose (% AD) was excreted as14CO2during, 48 hours after dosing, while an average of 0.01% AD was excreted as volatile organics. Averages of 25.20 and 5.44% AD were excreted in urine and feces, respectively, during 48 hours after dosing. An average of 8.03% AD was recovered in cage rinses during 48 hours after dosing. The total excretion of radiolabel averaged 78.88% AD. The total recovery of radiolabel from each animal averaged 86.43% AD.
In the main experiment, a single oral dose of [14C]NBPT was administered at an average of 252 mglkg body weight (206 µCi/kg body weight) to 8 male Sprague-Dawley rats. An average of 35.42% AD was excreted as14CO2during 168 hours after dosing. Averages of 24.39 and 8.65% AD were excreted in urine and feces during 168 hours after dosing. An average of 11.67% AD was recovered in the cage rinses during 168 hours after dosing. The total excretion of radiolabel averaged 80.12% AD. Whole blood, spleen, kidneys, liver, mesenteric fat and carcass were analyzed for radiolabel content. Radiolabel in whole blood, spleen, kidneys, liver, mesenteric fat and carcass averaged 2.96,5.05,6.34, 12.64,9.88 and 5.83 µg-equiv/g, respectively. The %AD in whole blood, spleen, kidneys, liver, mesenteric fat and carcass averaged 0.10,0.01,0.03,0.29,0.01 and 2.49%, respectively. The total recovery of radiolabel averaged 83.04% AD.
Four of the eight rats had jugular cannulae surgically implanted prior to dosing. Blood samples were collected from each animal through the cannulae at 1,2,4,6,8, 10, 12, 16, 24, 48, 72, 96 and l20 hours after dosing, and through the dorsal aorta at termination 168 hours after dosing, and then analyzed for radiolabel content. The peak concentration (Cmax) observed at any of the sampling times averaged 80.18 flg-equiv/g. The sampling time at which the peak concentration was observed (tmax), was 1 or 2 hours after dosing.
Results:
After the tmaxthe blood level rapidly decreased to less than 14% of the Cmaxby 24 hours after dosing and then declined to less than 5% by 168 hours.
Two major metabolites of NBPT were found in the urine samples from rats which had been treated with [14C]NBPT. The metabolites were N-(n-butyl)-thiophosphoric diamide and the glucuronic acid conjugate of NBPT
[14C]NBPT was eliminated from male Sprague-Dawley rats during 168 hours after a single oral dosing, mainly via expired air as14CO2and via urine, with averages of 35.42 and 24.39% AD, respectively. The total excretion of radiolabel was an average of 80.12% AD during 168 hours after dosing. Rat liver contained the highest level of radiolabel of all measured tissues (12.64 µg-equiv/g), but still contained less than 0.29% AD. No other tissue was found to contain residues above 10 µg-equiv/g or 0.10% AD except carcass contained 2.49% AD (5.83 µg-equiv/g).
There was a rapid absorption of [14C]NBPT equivalent residues into the systemic circulation following dosing. After the peak blood level. the blood level indicated a biphasic declination. The first phase was rapid and the second was slower.
Conclusion
NBPT appears to be biotransformed to N-(n-butyl)thiophosphoric diamide and the glucuronic acid conjugate of NBPT which then hydrolyzes to N-(n-butyl)thiophosphoric diamide. Both metabolites appear to be readily excreted in the urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.